https://www.selleckchem.com/products/mk-8245.html
a novel, externally validated approach which may hold potential to facilitate more targeted use of G-CSFs in the future.Controlling the time and dose of nanoparticulate drug delivery by administration of small molecule drugs holds promise for efficient and safer therapies. This study describes a versatile approach of exploiting antibody-ligand interactions for the design of small molecule-responsive nanocarrier and nanocomposite systems. For this purpose, antibody fragments (scFvs) specific for two distinct small molecule ligands are de
Like
Comment
Share
